# A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

> **NCT04009291** · PHASE2 · COMPLETED · sponsor: **Ascendis Pharma A/S** · enrollment: 59 (actual)

## Conditions studied

- Hypoparathyroidism
- Endocrine System Diseases
- Parathyroid Diseases

## Interventions

- **COMBINATION_PRODUCT:** TransCon PTH
- **COMBINATION_PRODUCT:** Placebo for TransCon PTH

## Key facts

- **NCT ID:** NCT04009291
- **Lead sponsor:** Ascendis Pharma A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-27
- **Primary completion:** 2020-03-06
- **Final completion:** 2025-04-17
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04009291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04009291, "A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04009291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*